NORTHERN TRUST CORP - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 2 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2018$74,000
-76.1%
375,134
-45.2%
0.00%
Q3 2018$309,000
-41.3%
684,893
-34.4%
0.00%
Q2 2018$526,000
-89.5%
1,043,770
-51.6%
0.00%
-100.0%
Q1 2018$5,026,000
-16.5%
2,156,960
+1.7%
0.00%
-50.0%
Q4 2017$6,020,000
+2.5%
2,120,027
+3.2%
0.00%0.0%
Q3 2017$5,875,000
+17.7%
2,054,358
+1.7%
0.00%
+100.0%
Q2 2017$4,992,000
-23.2%
2,020,797
+12.2%
0.00%
-50.0%
Q1 2017$6,502,000
+2.6%
1,801,136
+0.6%
0.00%0.0%
Q4 2016$6,338,000
-7.0%
1,790,481
+6.1%
0.00%0.0%
Q3 2016$6,817,000
+15.8%
1,687,213
+25.8%
0.00%0.0%
Q2 2016$5,887,000
+40.4%
1,341,064
+21.3%
0.00%
+100.0%
Q1 2016$4,192,000
-75.7%
1,105,693
+0.3%
0.00%
-83.3%
Q4 2015$17,281,000
+51.0%
1,102,076
+1.5%
0.01%
+50.0%
Q3 2015$11,446,000
-57.2%
1,086,042
+2.4%
0.00%
-50.0%
Q2 2015$26,748,000
-6.6%
1,060,633
+3.2%
0.01%
-11.1%
Q1 2015$28,641,000
+58.0%
1,027,691
+3.5%
0.01%
+80.0%
Q4 2014$18,124,000
+37.9%
993,089
-2.0%
0.01%
+25.0%
Q3 2014$13,140,000
-25.2%
1,013,873
-5.8%
0.00%
-20.0%
Q2 2014$17,569,000
-14.8%
1,076,511
-7.8%
0.01%
-16.7%
Q1 2014$20,633,000
-33.2%
1,167,655
-8.5%
0.01%
-40.0%
Q4 2013$30,902,000
-23.6%
1,276,413
+11.8%
0.01%
-28.6%
Q3 2013$40,467,000
+124.7%
1,142,171
-1.0%
0.01%
+100.0%
Q2 2013$18,010,0001,153,7570.01%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q1 2019
NameSharesValueWeighting ↓
KLP Enterprises, LLC 6,865,006$3,457,000100.00%
Meditor Group Ltd 6,312,700$3,179,0000.62%
TSP Capital Management Group, LLC 1,328,207$669,0000.34%
GREAT POINT PARTNERS LLC 804,483$405,0000.06%
Telemetry Investments, L.L.C. 252,300$127,0000.05%
Centiva Capital, LP 187,749$95,0000.02%
Benchmark Capital Advisors 54,400$27,0000.02%
GSA CAPITAL PARTNERS LLP 639,800$322,0000.02%
BOENNING & SCATTERGOOD, INC. 79,400$40,0000.01%
LMR Partners LLP 408,846$206,0000.01%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders